Ástralía - enska - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.1 mg (equivalent: pemetrexed, qty 500 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 1208.21 mg (equivalent: pemetrexed, qty 1000 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.82 mg (equivalent: pemetrexed, qty 100 mg) - injection, concentrated - excipient ingredients: trometamol; hydrochloric acid; sodium hydroxide; water for injections; monothioglycerol; citric acid - malignant pleural mesothelioma,pemetrexed ever pharma, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed ever pharma in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed ever pharma as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - not applicable

Evrópusambandið - enska - EMA (European Medicines Agency)

novo nordisk a/s - catridecacog - blood coagulation disorders, inherited - antihemorrhagics - long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-xiii-a-subunit deficiency.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - neutral insulin, human, pyr 100 iu/ml;   - solution for injection - 100 iu/ml - active: neutral insulin, human, pyr 100 iu/ml   excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc - treatment of diabetes mellitus. furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - neutral insulin, human, pyr 100 iu/ml;   - solution for injection - 100 iu/ml - active: neutral insulin, human, pyr 100 iu/ml   excipient: glycerol hydrochloric acid metacresol sodium hydroxide water for injection zinc - treatment of diabetes mellitus. furthermore indicated for the initial stabilisation of diabetes, during treatment of diabetic ketoacidosis and the hyperosmolar non ketotic syndrome, and during stress situations such as severe infections and major surgery in diabetic patients.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - glucagon hydrochloride 1mg (recombinant);  ;   - solution for injection - 1 mg - active: glucagon hydrochloride 1mg (recombinant)     excipient: lactose monohydrate water for injection - therapeutic treatment of severe hypoglycaemic reactions, which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. to prevent the occurrence of secondary hypoglycaemia, oral carbohydrate should be given to restore the hepatic glycogen when the patient has responded to the treatment. the mechanism and hence treatment of sulfonylurea-induced hypoglycaemia differs from that of severe insulin-induced hypoglycaemia in some important ways. consciousness should preferably be restored by the administration of intravenous glucose. if glucagon is used due to the unavailability of intravenous glucose (e.g. before reaching a hospital) care should be taken to protect against secondary hypoglycaemia with constant monitoring of the patient's blood sugar level by medical personnel. subsequent administration of intravenous glucose may be required.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - insulin detemir 100 u/ml - solution for injection - 100 u/ml - active: insulin detemir 100 u/ml excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol sodium chloride sodium hydroxide water for injection zinc - for the treatment of diabetes mellitus

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - isophane insulin, human, pyr 70 iu/ml;  ; neutral insulin, human, pyr 30 iu/ml;   - suspension for injection - active: isophane insulin, human, pyr 70 iu/ml   neutral insulin, human, pyr 30 iu/ml   excipient: dibasic sodium phosphate dihydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc - treatment of diabetes mellitus.